Alto Neuroscience, Inc. (ANRO)

Alto Neuroscience Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	137.82	168.23	82.55	48.34	25.71
Cash & Short-Term Investments	137.82	168.23	82.55	48.34	25.71
Cash Growth	-24.15%	103.79%	70.75%	88.07%	-
Accounts Receivable	-	-	-	-	1.5
Other Receivables	-	-	-	0.33	-
Total Trade Receivables	-	-	-	0.33	1.5
Other Current Assets	1.63	1.11	2.84	0.54	0.48
Total Current Assets	139.45	169.34	85.39	49.22	27.68
Net Property, Plant & Equipment	6.49	7.7	1.11	1.17	1.06
Other Long-Term Assets	1.07	0.5	0.13	0.46	0.05
Total Assets	147.01	177.54	86.63	50.85	28.79
Accounts Payable	2.06	1.58	1.07	1.61	0.6
Accrued Expenses	6.99	8.43	4.54	3.95	1.21
Total Current Liabilities	9.05	10.01	5.61	5.56	1.81
Long-Term Debt	20.31	10.25	9.86	9.47	-
Long-Term Leases	3.97	4.52	-	-	-
Other Long-Term Liabilities	2.12	1.3	1.35	2	1.3
Total Long-Term Liabilities	26.4	16.07	11.21	11.47	1.3
Total Liabilities	35.45	26.08	16.82	17.03	3.11
Common Stock	0	0	-	-	-
Additional Paid-in Capital	296.99	289.95	5.37	2.3	0.49
Accumulated Other Comprehensive Income	0.01	-0.1	-0.08	-0.05	-0.02
Retained Earnings	-185.45	-138.4	-76.97	-40.66	-12.95
Total Common Shareholders' Equity	111.56	151.46	-71.67	-38.41	-12.48
Minority Interest	-	-	141.48	72.24	38.16
Shareholders' Equity	111.56	151.46	69.81	33.83	25.69
Total Liabilities & Equity	147.01	177.54	86.63	50.85	28.79
Total Debt	24.28	14.77	9.86	9.47	0
Net Cash (Debt)	113.54	153.46	72.69	38.88	25.71
Net Cash Growth	-26.02%	111.12%	86.96%	51.25%	-
Net Cash Per Share	4.21	6.24	19.48	11.28	-
Book Value	111.56	151.46	-71.67	-38.41	-12.48
Book Value Per Share	4.13	6.16	-19.21	-11.15	-
Tangible Book Value	111.56	151.46	-71.67	-38.41	-12.48
Tangible Book Value Per Share	4.13	6.16	-19.21	-11.15	-

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q